$286.94
Value $5.7B
LGND and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$286.94
Value $5.7B
$1,351.12
Value $1.27T
Ligand Pharmaceuticals (LGND) has a market value of $5.7B and Eli Lilly and Company (LLY) $1.27T. Over the last year, with dividends, LGND moved +38.6% and LLY +32.0%. The P/E is 111.2 for LGND and 46.2 for LLY. Dividend yield: LGND none, LLY 0.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LGND$5.7B
LLY$1.27T
LLY is 223 times LGND
Revenue, 12 months
LGND$254M
LLY$86.5B
LLY is 341 times LGND
Net income, 12 months
LGND$51M
LLY$27.6B
LLY is 536 times LGND
Operating margin
LGND9.3%
LLY–
ROIC
LGND1.3%
LLY35.5%
34.2 points apart
P/E
LGND111.2
LLY46.2
LGND is 2.4 times LLY
Dividend yield
LGND0.0%
LLY0.5%
0.5 points apart
5-year return
LGND+186.2%
LLY+439.8%
253.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LGND+186.2%
LLY+439.8%
| Period | LGNDWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +38.6%Price +38.6% | +32.0%Price +31.2% |
| 3 years since November 17, 2023 | +396.3%+70.6% a yearPrice +396.3% | +132.9%+32.6% a yearPrice +128.3% |
| 5 years since November 18, 2021 | +186.2%+23.4% a yearPrice +186.2% | +439.8%+40.1% a yearPrice +417.0% |
| 10 years since November 21, 2016 | +328.7%+15.7% a yearPrice +328.7% | +1,950.7%+35.3% a yearPrice +1,662.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LGNDLigand PharmaceuticalsLLYEli Lilly and Company
| Price | $286.94 | $1,351.12 |
|---|---|---|
| Market value | $5.7B | $1.27T |
| Enterprise value (EV) | $6.4B | $1.32T |
| P/E | 111.2 | 46.2 |
| P/E, 5-year median | 30.8 | 49.9 |
| P/B | 6.0 | 31.7 |
| EV/EBIT | 271.4 | 37.9 |
| Free cash flow yield | 1.6% | 1.5% |
| Revenue, 12 months | $254M | $86.5B |
|---|---|---|
| Net income, 12 months | $51M | $27.6B |
| Free cash flow, 12 months | $91M | $19.7B |
| Earnings per share, 12 months | $2.30 | $30.81 |
| Revenue growth, year on year | 60.4% | 44.7% |
| Revenue growth a year, past | +10.4%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | – | +27.6%over 5 years |
| Gross margin | – | 83.6% |
|---|---|---|
| Operating margin | 9.3% | – |
| Net margin | 20.3% | 31.9% |
| ROIC | 1.3% | 35.5% |
| ROE | 5.3% | 88.6% |
| Cash | $447M | $4.9B |
|---|---|---|
| Total debt | $1.2B | $49.5B |
| Net debt / EBITDA | 11.9 | 1.2 |
| Interest cover | 2.9× | 38.9× |
| Dividend yield | – | 0.5% |
|---|---|---|
| Dividend per share, 12 months | – | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | 0.3% | 0.3% |
| Shareholder yield | 0.3% | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.27T) is about 222.8 times Ligand Pharmaceuticals ($5.7B), at today's prices.
Since November 21, 2016, LGND's price moved +328.7% and LLY's +1,662.9%. With dividends: LGND +328.7% (+15.7% a year), LLY +1,950.7% (+35.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Ligand Pharmaceuticals and 0.47% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.
At today's price, the P/E is 111.2 for LGND and 46.2 for LLY. The median of the last five years was 30.8 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 20.3% for Ligand Pharmaceuticals and 31.9% for Eli Lilly and Company, and the operating margin 9.3% and –. Revenue was $254M and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.